KPV FDA PCAC July 2026: 503A Review and Research Access

The FDA's Pharmacy Compounding Advisory Committee (PCAC) is scheduled to convene on July 23, 2026 to evaluate the 503A bulk drug substance status of KPV, among several other peptide compounds. For researchers and clinicians who rely on 503A compounding pharmacies as the regulated domestic source of this tripeptide, the committee's determination carries direct implications for continued research access. This article explains KPV's regulatory history, how the PCAC evaluation applies to a compound of this class, and what outcome scenarios researchers should anticipate.

Research reference only. All information on this page is a summary of peer-reviewed scientific literature and regulatory documentation. It does not constitute medical or legal advice. See the KPV compound library profile for full compound data, and the PCAC overview article for context on all compounds under review at the July 2026 meeting.

What KPV is and why it is compounded

KPV (Lys-Pro-Val) is a synthetic C-terminal tripeptide fragment of α-melanocyte-stimulating hormone (α-MSH), a neuropeptide belonging to the melanocortin family. The three-amino-acid sequence — lysine, proline, valine — represents the active motif responsible for α-MSH's anti-inflammatory and immunomodulatory properties in preclinical models, without the melanotropic receptor binding associated with the full α-MSH sequence.

Published research has primarily investigated KPV in the context of gastrointestinal inflammation and gut barrier integrity. Dalmasso et al. (2008, Inflammatory Bowel Diseases) demonstrated that KPV reduced colitis severity in murine TNBS models through suppression of NF-κB-mediated inflammatory signaling and reduction in TNF-α and IL-6 cytokine secretion. More recent work has investigated oral and nanoparticle-encapsulated delivery formats, with Vong et al. (2020, Science Advances) demonstrating that orally delivered KPV-loaded nanoparticles retained anti-inflammatory activity in the gut lumen of colitis mouse models — a finding relevant to research access scenarios given the compound's short systemic half-life in unencapsulated form.

Because no FDA-approved drug containing KPV as an active pharmaceutical ingredient exists, its clinical and investigational use in the United States has occurred through Section 503A compounding pharmacies. The PCAC evaluation is the regulatory event that will determine whether that channel remains open.

The 503A framework and KPV's current classification

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies preparing individualized prescriptions for specific patients. The law permits use of bulk drug substances only if they appear on an FDA-maintained positive list, are components of FDA-approved drugs, or meet specified alternative criteria. The PCAC serves as the advisory committee evaluating whether nominated bulk drug substances should be placed on, maintained on, or removed from that positive list.

KPV is currently under 503A Category 2 review — a designation applied to compounds that the FDA has identified as warranting advisory committee evaluation due to questions about clinical evidence adequacy, compounding feasibility, or the existence of suitable commercially available alternatives. Like BPC-157, TB-500, and Semax — also scheduled for July 2026 review — KPV's Category 2 status reflects regulatory scrutiny rather than a final determination.

The July 23, 2026 meeting gives nominators who have submitted clinical need documentation and updated evidence the opportunity for direct committee consideration.

The research evidence base

The PCAC evaluates 503A bulk drug substance nominations against the totality of available evidence for safety and effectiveness — not against the higher bar required for drug approval, but against a standard of clinical plausibility and demonstrated compounding need.

Gastrointestinal research: The strongest and most replicated body of KPV preclinical research concerns its anti-inflammatory activity in intestinal models. Dalmasso et al. (2008) established NF-κB suppression and cytokine reduction in both in vitro colonocyte models and in vivo TNBS colitis. Kannengiesser et al. (2011, Regulatory Peptides) confirmed anti-inflammatory KPV activity in DSS-induced colitis models, demonstrating reduced histological damage scores and preservation of tight junction protein expression. These IBD-model findings represent the most clinically translatable preclinical data supporting KPV's nomination.

Delivery research: Because KPV is a tripeptide subject to rapid enzymatic degradation when administered systemically, published research has explored encapsulation strategies including PEGylated nanoparticle carriers and hydrogel formulations for local colonic delivery. This body of work, while scientifically valuable, also illustrates the compounding complexity the PCAC may consider under its Factor 1 analysis — stability and delivery format present greater challenges for KPV than for longer, more structurally stable peptides.

Immunomodulatory research beyond the gut: Separate from GI research, KPV has been investigated in dermatological inflammation models. Richard et al. (2005, Journal of Investigative Dermatology) reported reduced inflammatory infiltration and cytokine levels in KPV-treated skin inflammation models, suggesting mechanism relevance beyond the GI tract. Melanocortin receptor binding studies have confirmed KPV interaction with MC3R and MC4R, the receptors most associated with peripheral anti-inflammatory rather than melanotropic signaling.

Human data: No completed Phase II or Phase III randomized controlled trials of KPV as a standalone drug candidate have been published. Human data is restricted to case reports and small observational cohorts from compounding pharmacy practice, which represents the same evidentiary limitation facing most 503A-nominated peptides in the July 2026 docket.

The no-approved-equivalent argument

The presence or absence of an FDA-approved commercial equivalent is among the most determinative factors in PCAC 503A evaluations. For KPV, the analysis is unambiguous: no FDA-approved drug contains KPV as an active ingredient. No NDA or ANDA referencing KPV exists in FDA's drug databases. The compound exists domestically only within the compounding channel.

The committee will also assess whether approved drugs treating the same clinical conditions that KPV compounders address could substitute for the compounded preparation. In the primary indication context — inflammatory bowel disease — FDA-approved biologics (anti-TNF antibodies, anti-integrin antibodies, JAK inhibitors) and aminosalicylates represent alternative options. Whether the committee views these as "suitable commercial alternatives" sufficient to reduce the clinical need for compounded KPV, or whether KPV's distinct mechanism and local delivery characteristics constitute a meaningfully different therapeutic context, is a substantive question the July 23 evaluation will address.

What the PCAC evaluates: four-factor analysis applied to KPV

Factor 1 — Physical and chemical characteristics: KPV's tripeptide structure is simple relative to larger peptides — three amino acids with a molecular weight of approximately 339 Da. Its small size confers solubility advantages but also extreme susceptibility to peptidase-mediated hydrolysis in systemic circulation. Compounding in lyophilized form for reconstitution and injection, or in encapsulated oral delivery formats, presents technical challenges that the committee will evaluate for compounding feasibility.

Factor 2 — Safety and effectiveness evidence: The preclinical safety profile of KPV is favorable across the published literature, with no reported significant toxicological signals in rodent models across the dose ranges studied. The effectiveness record is primarily preclinical, with robust animal model data for GI anti-inflammatory activity and more limited data in other contexts. The committee will weigh whether this evidence base meets the 503A standard of clinical plausibility.

Factor 3 — Historical use in compounding: KPV has accumulated documented prescribing history through 503A compounders, primarily in inflammatory bowel and colitis-associated contexts. Compounding records and nominator submissions are expected to present this usage data to the committee.

Factor 4 — Nature of the condition treated: The primary patient populations for whom KPV has been compounded include individuals with inflammatory bowel disease and other conditions involving gut inflammatory pathology. The committee will assess whether these patient populations have unmet clinical needs that existing approved therapies do not fully address and that KPV's distinct mechanism and delivery profile may serve.

Outcome scenarios following July 23, 2026

Scenario A — Upgraded to Category 1 (positive listing). The committee finds sufficient clinical evidence, acceptable compounding characteristics, and no adequate commercial substitute. 503A pharmacies may continue compounding KPV without regulatory disruption. This is the outcome most favorable to continued research access.

Scenario B — Maintained at Category 2. The evidence is seen as insufficient for positive listing but not definitively adverse. The compound remains in a regulatory holding pattern, with continued compounding availability in the near term but ongoing uncertainty.

Scenario C — Restricted or prohibited from 503A compounding. If the committee recommends, and FDA ultimately finalizes, exclusion from the 503A Bulks List, 503A pharmacies would be prohibited from using KPV as a bulk drug substance. Given the absence of any alternative regulated domestic source, this outcome would effectively end clinically supervised compounded KPV access in the United States.

Regulatory timeline after the meeting

An advisory committee recommendation does not constitute final regulatory action. Following the July 23 meeting, FDA will typically publish the committee's recommendations and open a public comment docket. Formal rulemaking or guidance publication — representing the final agency determination — has historically followed PCAC meetings by six months to over a year, depending on comment volume and compound-specific complexity. Researchers and clinicians with standing to comment have that window to submit additional evidence or clinical need data into the FDA record before a final determination is issued.

Summary

KPV's July 23, 2026 PCAC review is the central regulatory event for this compound's 503A availability. Its strongest argument for continued access is the complete absence of any FDA-approved equivalent containing KPV as an active ingredient. The quality of its preclinical evidence base — particularly the IBD model literature — provides a scientifically coherent case for clinical plausibility. The key uncertainties are whether limited human data satisfies the committee's evidentiary threshold and whether the compounding delivery challenges associated with a short-half-life tripeptide will weigh against positive listing.

For full compound chemistry, mechanism data, and preclinical literature citations, see the KPV compound library profile. For the broader regulatory context of the July 2026 PCAC review, see the PCAC overview article. For a direct comparison of KPV and BPC-157 — two compounds sharing the July 23 docket — see the BPC-157 vs KPV comparison.